• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

慢性肾衰竭中脂质代谢失调的原因。

Causes of dysregulation of lipid metabolism in chronic renal failure.

作者信息

Vaziri Nosratola D

机构信息

Division of Nephrology and Hypertension, Departments of Medicine, Physiology and Biophysics, University of California, Irvine, California, USA.

出版信息

Semin Dial. 2009 Nov-Dec;22(6):644-51. doi: 10.1111/j.1525-139X.2009.00661.x.

DOI:10.1111/j.1525-139X.2009.00661.x
PMID:20017835
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2874323/
Abstract

End-stage renal disease (ESRD) is associated with accelerated atherosclerosis and premature death from cardiovascular disease. These events are driven by oxidative stress inflammation and lipid disorders. ESRD-induced lipid abnormalities primarily stem from dysregulation of high-density lipoprotein (HDL), triglyceride-rich lipoprotein metabolism, and oxidative modification of lipoproteins. In this context, production and plasma concentration of Apo-I and Apo-II are reduced, HDL maturation is impaired, HDL composition is altered, HDL antioxidant and anti-inflammatory functions are depressed, clearance of triglyceride-rich lipoproteins and their atherogenic remnants is impaired, their composition is altered, and their plasma concentration is elevated in ESRD. The associated defect in HDL maturation is largely caused by acquired lecithin-cholesterol acyltransferase deficiency while its triglyceride enrichment is due to hepatic lipase deficiency. Hypertriglyceridemia, abnormal composition, and impaired clearance of triglyceride-rich lipoproteins and their remnants are mediated by down-regulation of lipoprotein lipase, hepatic lipase, very low-density lipoprotein (VLDL) receptor, and LDL receptor-related protein, relative reduction in ApoC-II/ApoC-III ratio, up-regulation of acyl-CoA cholesterol acyltransferase, and elevated plasma level of cholesterol ester-poor prebeta HDL. Impaired clearance and accumulation of oxidation-prone VLDL and chylomicron remnants and abnormal LDL composition in the face of oxidative stress and inflammation favors their uptake by macrophages and resident cells in the artery wall. The effect of heightened influx of lipids is compounded by impaired HDL-mediated reverse cholesterol transport leading to foam cell formation which is the central event in atherosclerosis plaque formation and subsequent plaque rupture, thrombosis, and tissue damage.

摘要

终末期肾病(ESRD)与动脉粥样硬化加速及心血管疾病导致的过早死亡相关。这些事件由氧化应激、炎症和脂质紊乱驱动。ESRD诱导的脂质异常主要源于高密度脂蛋白(HDL)失调、富含甘油三酯的脂蛋白代谢以及脂蛋白的氧化修饰。在这种情况下,载脂蛋白I(Apo-I)和载脂蛋白II(Apo-II)的产生及血浆浓度降低,HDL成熟受损,HDL组成改变,HDL抗氧化和抗炎功能受抑,富含甘油三酯的脂蛋白及其致动脉粥样硬化残余物的清除受损,其组成改变,且在ESRD中其血浆浓度升高。HDL成熟相关缺陷很大程度上由获得性卵磷脂胆固醇酰基转移酶缺乏引起,而其甘油三酯富集则归因于肝脂酶缺乏。高甘油三酯血症、富含甘油三酯的脂蛋白及其残余物的异常组成和清除受损是由脂蛋白脂肪酶、肝脂酶、极低密度脂蛋白(VLDL)受体和低密度脂蛋白受体相关蛋白的下调、ApoC-II/ApoC-III比值相对降低、酰基辅酶A胆固醇酰基转移酶上调以及胆固醇酯含量低的前β-HDL血浆水平升高介导的。面对氧化应激和炎症,易氧化的VLDL和乳糜微粒残余物的清除受损和积累以及LDL异常组成有利于它们被动脉壁中的巨噬细胞和驻留细胞摄取。脂质流入增加的影响因HDL介导的胆固醇逆向转运受损而加剧,导致泡沫细胞形成,这是动脉粥样硬化斑块形成以及随后斑块破裂、血栓形成和组织损伤的核心事件。

相似文献

1
Causes of dysregulation of lipid metabolism in chronic renal failure.慢性肾衰竭中脂质代谢失调的原因。
Semin Dial. 2009 Nov-Dec;22(6):644-51. doi: 10.1111/j.1525-139X.2009.00661.x.
2
Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences.慢性肾衰竭的血脂异常:性质、机制及潜在后果
Am J Physiol Renal Physiol. 2006 Feb;290(2):F262-72. doi: 10.1152/ajprenal.00099.2005.
3
Abnormalities in uremic lipoprotein metabolism and its impact on cardiovascular disease.尿毒症脂蛋白代谢异常及其对心血管疾病的影响。
Am J Kidney Dis. 2001 Oct;38(4 Suppl 1):S14-9. doi: 10.1053/ajkd.2001.27384.
4
HDL metabolism and activity in chronic kidney disease.慢性肾脏病中的高密度脂蛋白代谢和功能。
Nat Rev Nephrol. 2010 May;6(5):287-96. doi: 10.1038/nrneph.2010.36. Epub 2010 Mar 23.
5
Lipid disorders and their relevance to outcomes in chronic kidney disease.脂质代谢紊乱及其与慢性肾脏病患者预后的相关性。
Blood Purif. 2011;31(1-3):189-96. doi: 10.1159/000321845. Epub 2011 Jan 10.
6
Lipotoxicity and impaired high density lipoprotein-mediated reverse cholesterol transport in chronic kidney disease.脂毒性和慢性肾脏病中高密度脂蛋白介导的胆固醇逆转运受损。
J Ren Nutr. 2010 Sep;20(5 Suppl):S35-43. doi: 10.1053/j.jrn.2010.05.010.
7
Salutary effects of hemodialysis on low-density lipoprotein proinflammatory and high-density lipoprotein anti-inflammatory properties in patient with end-stage renal disease.终末期肾病患者血液透析对低密度脂蛋白促炎和高密度脂蛋白抗炎特性的有益作用。
J Natl Med Assoc. 2011 Jun;103(6):524-33. doi: 10.1016/s0027-9684(15)30368-0.
8
The role of oxidative stress-altered lipoprotein structure and function and microinflammation on cardiovascular risk in patients with minor renal dysfunction.氧化应激改变的脂蛋白结构与功能及微炎症在轻度肾功能不全患者心血管风险中的作用
J Am Soc Nephrol. 2004 Mar;15(3):538-48. doi: 10.1097/01.asn.0000111744.00916.e6.
9
Down-regulation of hepatic lecithin:cholesterol acyltransferase gene expression in chronic renal failure.慢性肾衰竭时肝脏卵磷脂胆固醇酰基转移酶基因表达下调。
Kidney Int. 2001 Jun;59(6):2192-6. doi: 10.1046/j.1523-1755.2001.00734.x.
10
Lipid and lipoprotein metabolism in chronic kidney disease.慢性肾脏病中的脂质与脂蛋白代谢
J Ren Nutr. 2009 Jan;19(1):73-7. doi: 10.1053/j.jrn.2008.10.011.

引用本文的文献

1
High-Density Lipoprotein in Patients with Diabetic Kidney Disease: Friend or Foe?糖尿病肾病患者中的高密度脂蛋白:是友还是敌?
Int J Mol Sci. 2025 Feb 16;26(4):1683. doi: 10.3390/ijms26041683.
2
HDL and chronic kidney disease.高密度脂蛋白与慢性肾脏病
Atheroscler Plus. 2023 Apr 18;52:9-17. doi: 10.1016/j.athplu.2023.04.001. eCollection 2023 Jun.
3
Spectrally and Time-Resolved Fluorescence Imaging of 22-NBD-Cholesterol in Human Peripheral Blood Mononuclear Cells in Chronic Kidney Disease Patients.慢性肾脏病患者外周血单个核细胞中 22-NBD-胆固醇的时间分辨荧光成像光谱研究。

本文引用的文献

1
Plasma phospholipid transfer protein, cholesteryl ester transfer protein and lecithin:cholesterol acyltransferase in end-stage renal disease (ESRD).终末期肾病(ESRD)中的血浆磷脂转运蛋白、胆固醇酯转运蛋白和卵磷脂胆固醇酰基转移酶
Nephrol Dial Transplant. 2009 Aug;24(8):2541-6. doi: 10.1093/ndt/gfp120. Epub 2009 Mar 18.
2
Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease.慢性肾脏病中高密度脂蛋白抗氧化活性受损。
Transl Res. 2009 Feb;153(2):77-85. doi: 10.1016/j.trsl.2008.11.007. Epub 2008 Dec 10.
3
Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis.
Molecules. 2021 Nov 11;26(22):6800. doi: 10.3390/molecules26226800.
4
A Matched Case-Control Study of Noncholesterol Sterols and Fatty Acids in Chronic Hemodialysis Patients.慢性血液透析患者非胆固醇甾醇和脂肪酸的配对病例对照研究
Metabolites. 2021 Nov 12;11(11):774. doi: 10.3390/metabo11110774.
5
Investigation of Gene Cluster Single Nucleotide Polymorphisms in End-Stage Renal Disease Compared With Normal Controls.与正常对照相比,终末期肾病中基因簇单核苷酸多态性的研究。
Front Genet. 2021 Sep 16;12:716151. doi: 10.3389/fgene.2021.716151. eCollection 2021.
6
Lipoprotein Abnormalities in Chronic Kidney Disease and Renal Transplantation.慢性肾脏病及肾移植中的脂蛋白异常
Life (Basel). 2021 Apr 5;11(4):315. doi: 10.3390/life11040315.
7
Remnant cholesterol is prospectively associated with cardiovascular disease events and all-cause mortality in kidney transplant recipients: the FAVORIT study.移植后胆固醇残留与肾移植受者的心血管疾病事件和全因死亡率有前瞻性关联:FAVORIT 研究。
Nephrol Dial Transplant. 2022 Jan 25;37(2):382-389. doi: 10.1093/ndt/gfab068.
8
Risk Factors for Chronic Kidney Disease in Older Adults with Hyperlipidemia and/or Cardiovascular Diseases in Taipei City, Taiwan: A Community-Based Cross-Sectional Analysis.台湾台北市高血脂和/或心血管疾病老年患者慢性肾脏病的危险因素:一项基于社区的横断面分析。
Int J Environ Res Public Health. 2020 Nov 25;17(23):8763. doi: 10.3390/ijerph17238763.
9
The Role and Function of HDL in Patients with Chronic Kidney Disease and the Risk of Cardiovascular Disease.高密度脂蛋白在慢性肾脏病患者中的作用和功能及心血管疾病风险。
Int J Mol Sci. 2020 Jan 17;21(2):601. doi: 10.3390/ijms21020601.
10
Atorvastatin Improves Hepatic Lipid Metabolism and Protects Renal Damage in Adenine-Induced Chronic Kidney Disease in Sprague-Dawley Rats.阿托伐他汀改善腺嘌呤诱导的慢性肾脏病 Sprague-Dawley 大鼠的肝脂代谢并保护肾脏损伤。
Biomed Res Int. 2019 Nov 5;2019:8714363. doi: 10.1155/2019/8714363. eCollection 2019.
阿托伐他汀对2型糖尿病血液透析患者炎症及预后的影响
Kidney Int. 2008 Dec;74(11):1461-7. doi: 10.1038/ki.2008.484. Epub 2008 Sep 24.
4
Hyperlipidemia in chronic kidney disease.慢性肾脏病中的高脂血症
Int J Artif Organs. 2007 Nov;30(11):987-92. doi: 10.1177/039139880703001107.
5
Molecular regulation of HDL metabolism and function: implications for novel therapies.高密度脂蛋白代谢与功能的分子调控:对新型疗法的启示
J Clin Invest. 2006 Dec;116(12):3090-100. doi: 10.1172/JCI30163.
6
Cell surface adenylate kinase activity regulates the F(1)-ATPase/P2Y (13)-mediated HDL endocytosis pathway on human hepatocytes.细胞表面腺苷酸激酶活性调节人肝细胞上F(1)-ATP酶/P2Y(13)介导的高密度脂蛋白内吞途径。
Cell Mol Life Sci. 2006 Dec;63(23):2829-37. doi: 10.1007/s00018-006-6325-y.
7
ATP-Binding cassette cholesterol transporters and cardiovascular disease.ATP结合盒式胆固醇转运蛋白与心血管疾病
Circ Res. 2006 Nov 10;99(10):1031-43. doi: 10.1161/01.RES.0000250171.54048.5c.
8
Myeloperoxidase: an inflammatory enzyme for generating dysfunctional high density lipoprotein.髓过氧化物酶:一种生成功能失调性高密度脂蛋白的炎症酶。
Curr Opin Cardiol. 2006 Jul;21(4):322-8. doi: 10.1097/01.hco.0000231402.87232.aa.
9
Mechanisms of dyslipidemia of chronic renal failure.慢性肾衰竭血脂异常的机制。
Hemodial Int. 2006 Jan;10(1):1-7. doi: 10.1111/j.1542-4758.2006.01168.x.
10
Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences.慢性肾衰竭的血脂异常:性质、机制及潜在后果
Am J Physiol Renal Physiol. 2006 Feb;290(2):F262-72. doi: 10.1152/ajprenal.00099.2005.